Cargando…
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tes...
Autores principales: | Schmieder, Roberta, Hoffmann, Jens, Becker, Michael, Bhargava, Ajay, Müller, Tina, Kahmann, Nicole, Ellinghaus, Peter, Adams, Robert, Rosenthal, André, Thierauch, Karl-Heinz, Scholz, Arne, Wilhelm, Scott M, Zopf, Dieter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277327/ https://www.ncbi.nlm.nih.gov/pubmed/24347491 http://dx.doi.org/10.1002/ijc.28669 |
Ejemplares similares
-
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
por: Strumberg, D, et al.
Publicado: (2012) -
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
por: Zopf, Dieter, et al.
Publicado: (2016) -
Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017) -
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019) -
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
por: Daudigeos-Dubus, Estelle, et al.
Publicado: (2015)